EnteroBiotix announces positive results for IBS microbiome therapy
Biopharmaceutical company EnteroBiotix has announced positive final results from its TrIuMPH clinical trial, which is evaluating the company’s full-spectrum microbiome therapeutic for patients with irritable bowel syndrome with constipation (IBS-C) with constipation or diarrhoea (IBS-D).
The Phase IIa clinical trial included 122 UK patients and results show that EBX-102-02 demonstrated clinically meaningful improvements in the IBS symptom severity score (IBS-SSS) versus placebo. The trial assessed factors such as abdominal pain, bowel habit parameters, and IBS-specific quality of life.
EnteroBiotix states that clinically meaningful improvements in IBS-SSS for both IBS-C and IBS-D mean that EBX-102-02 has the potential to act as a single therapeutic approach for the two major disease subtypes.
The results build on the previously reported positive topline data from the IBS-C cohort reported in March 2025 as a late-breaking oral presentation at Digestive Disease Week in San Diego.
EnteroBiotix now plans to submit the full TrIuMPH dataset for peer-reviewed scientific publication and to initiate an IBS-C Phase II2b study in 2026, aligned with recent FDA regulatory advice.
Dr James McIlroy, CEO of EnteroBiotix, said: “The final TrIuMPH data demonstrate that EBX-102-02 has the potential to be a first-in-class, orally delivered, full-spectrum microbiome therapeutic for IBS, delivering clinically meaningful and durable improvements across multiple symptom domains in both IBS-C and IBS-D. Combined with a favourable safety profile and clear evidence of microbiome ecosystem restoration, these results strongly support advancement into our planned Phase IIb clinical trial with the goal of delivering a transformative treatment for patients with IBS.”
Mr Paul Goldsmith,Consultant General Surgeon at the University of Manchester NHS Trust and Chief Investigator of the TrIuMPH study, added: “IBS is a complex disease with a significant unmet medical need. The improvements in global symptom severity, abdominal pain, bowel habits and quality of life observed with EBX-102-02 in this study are clinically meaningful. Taken together, these data support continued development of EBX-102-02 across both IBS-C and IBS-D.”